Cowen analyst Yaron Werber lowered the firm’s price target on Exelixis to $20 from $21 and keeps an Outperform rating on the shares. The analyst said its preliminary Q4 report shows inline net product revenues and modest 2% q/q growth. He also noted its early pipeline continues to make steady progress and multiple IND filings are planned by 2024; but the ANDA case is expected to remain an overhang with a second trial starting in October 2023.
Published first on TheFly
See Insiders’ Hot Stocks on TipRanks >>
Read More on EXEL:
- Exelixis reports preliminary Q4 revenue $415M, consensus $414.83M
- NccRCC ‘material expansion opportunity’ for Exelixis, says William Blair
- Exelixis announces initiation of STELLAR-304 Phase 3 trial of zanzalintinib
- Exelixis names Dana Aftab next chief scientific officer
- Exelixis price target lowered to $32 from $35 at Truist
